secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXICURE, INC. (XCUR)
CIK:        0001698530
Form:       8-K
Filed at:   2024-06-17T23:59:59+00:00
Accession:  0001698530-24-000067
Event type: earnings
Sentiment:  negative
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Exicure reports Q1 net loss of $0.8M; cash only $0.2M by May 31, going concern
------------------------------------------------------------------------------

- Cash and equivalents $0.4M at March 31, 2024, falling to ~$0.2M by May 31.
- Received $0.7M loan from DGP Co., Ltd. after May 31; 6% interest, 10-month maturity.
- Revenue of $0.5M from patent license for cavrotolimod (hepatitis) with private biopharma.
- Net loss improved to $0.8M from $4.4M YoY due to cost cuts and license revenue.
- Company states existing cash insufficient; substantial near-term financing needed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1698530/000169853024000067/0001698530-24-000067-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1698530/000169853024000067/xcur-20240617.htm
  HTML page:      https://secwatch.observer/filing/0001698530-24-000067

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer